George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

Is HEXO Stock a Buy?

The Canadian cannabis grower and distributor had a dreadful 2019 that sent its shares tumbling to levels that could be tempting for bargain hunters.

Where Will Aurora Cannabis Be in 10 Years?

Like all pot stocks, Aurora is going through a rough patch at the moment. Should long-term investors take advantage of this downturn to build a position?